A unique story centered on innovation

Creation of Provence Technologies, a research and development laboratory in chemistry, the result of the fraternal union of the two founding partners: Michel FERAUD and Christophe BARALOTTO. The company is positioned as a subcontractor to biotechnology companies and international pharmaceutical groups. The company thus obtains its credentials in fields as varied as pharmacy, cosmetics and agrochemistry.

With a solid financial structure in place, Provence Technologies is launching several internal research programs. One of them concerns a new process for synthesizing methylene blue and results in 2006 in the filing of a global patent. This is followed a year later in 2007 by the creation of Provepharm, a subsidiary of Provence Technologies intended to develop and market this asset.

Obtaining a Centralized Marketing Authorization (MAA) paves the way for the commercialization of methylene blue Proveblue® in 30 European countries; authorities recognize the patient benefit.. 

Thus, Michel FERAUD, co-inventor of this patent with Babak SAYAH, also becomes President and surrounds himself with a team of professionals as well as a committee of internationally renowned experts. 

The group acquires a company specializing in the chemical synthesis of peptides and proteins for therapeutic use. This acquisition opens a new avenue of development for the company in the field of biological pharmaceutical actives.  Obtaining CE marking for its Methylene Blue, Provedye®, medical device. 

An important step has been taken: Provepharm obtains FDA approval to market ProvayBlue®, its injectable methylene blue, in the USA 

The company becomes Provepharm Life Solutions and launches its new brand identity. The story continues! Acquisition of GMP facilities for the entire workshop and its equipment. 

Provepharm Life Solutions has partnered with new strategic partners, ArchiMed and Téthys Invest.

Obtaining a syndicated loan of €42.5 million. 

Inauguration of the production workshop located on the Château Gombert site. 

Provepharm continues its growth and development of integrated, innovative solutions, with a new patent filing for the synthesis of Indigo carmine. Provepharm secures a new acquisition, Apollo Pharmaceuticals USA. This year was also marked by the launch of direct sales in France and the USA, allowing it to control its activities in these two key countries and work closely with healthcare professionals. 

Provepharm Life Solutions Raises €120 Million and Enables the Pharmaceutical Group to Reach a Decisive Milestone in the Realization of its Horizon 2025 Strategic Plan. 
The company is evolving its appearance and launching its new brand identity. This new graphic design embodies innovation, commitment, and modernity, in line with our growth. 

Obtaining Marketing Authorization (MA) in France and the US for a new product: Provingo® / Bludigo®, an injectable indigo carmine solution. 

Provepharm opens new offices in Newark, New Jersey, and continues its growth in North America and launches direct operations and sales in the United Kingdom. Obtaining 3 MAAs: Provingo® Indigo Carmine in Poland, Greece and Germany. Provepharm joins the very exclusive club of pioneering pharmaceutical companies certified B Corp. 

Obtaining Marketing Authorization (MA) for Blumyne® Indigo Carmine in the UK. Hélène Thomas joins as Deputy CEO to support Michel Feraud in implementing Provepharm’s overall strategy. 

Provepharm is refocusing on innovation and R&D, which have been the drivers of its growth and success for over 25 years. The company has entered into a strategic commercial alliance with Sagent Pharmaceuticals for the distribution of its products in the United States.